Skip to main content
Premium Trial:

Request an Annual Quote

Miragen Acquires microRNA Target Rights from T2cure

Premium

Miragen Therapeutics said this week that it has acquired from German biopharmaceutical firm T2cure the exclusive rights to technology and intellectual property related to the in vivo use of microRNA-92 as a therapeutic target.

According to the company, miR-92 is "a key regulator of neo-angiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders."

A particular member of the miRNA family, miR-92a, "serves as a valuable therapeutic target in the setting of ischemic disease," and potentially other vascular disorders such as atherosclerosis, Miragen added.

Specific terms of the agreement were not disclosed, although Miragen said that T2cure retains the right to use modulators of miR-92 for "ex vivo treatment of cellular therapeutics."

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.